Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389010 | 0.90 | OPRM1 (0.35) | BDKRB1LMNAOPRM1OPRK1PAX8 | |
| SCHEMBL5381807 | 0.87 | NPC1 (0.40) | BDKRB1FKBP1A | |
| SCHEMBL5387874 | 0.87 | HCRTR1 (0.36) | HCRTR1HCRTR2BDKRB1LMNAEPHX2 | |
| SCHEMBL5389019 | 0.76 | BDKRB1 (0.36) | BDKRB1LMNAOPRM1OPRK1 | |
| SCHEMBL5381885 | 0.74 | BDKRB1 (0.36) | BDKRB1LMNAOPRM1OPRK1HRH3 | |
| SCHEMBL5393649 | 0.74 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5381812 | 0.74 | FKBP1A (0.39) | BDKRB1LMNAFKBP1A | |
| SCHEMBL5377549 | 0.72 | BDKRB1 (0.39) | BDKRB1HRH3 | |
| SCHEMBL5392287 | 0.72 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5457823 | 0.72 | NR1H2 (0.40) | BDKRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | HCRTR1 542/4885HCRTR2 762/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.